Identification of successful prevention and treatment strategies for Alzheimer?s Disease (AD) has remained elusive, partially because clinical symptoms of AD have a late presentation in disease development, but also because there are not clear targets directly related to AD neuropathology for which definitive treatment is available. Thus, focusing on possible treatment and prevention targets that can be identified well before onset of clinical disease and which are known to be treatable is critical in addressing AD. The vascular contribution to cognitive impairment and dementia, including AD, offers an important opportunity for prevention and treatment. Further, evidence suggests that vascular risk factors, including hypertension and diabetes, as well as brain cerebrovascular changes (i.e. white matter hyperintensities), contribute most to the development of cognitive decline and dementia when they are present in midlife (well before clinical AD usually presents). Some of this evidence has been established by the ongoing Atherosclerosis Risk in Communities (ARIC) study, a community-based biracial cohort study of individuals from four US communities, with nearly 30 years of vascular risk factors and marker data, and its primary ancillary study, the ARIC Neurocognitive Study (ARIC- NCS). The ARIC-PET Amyloid Imaging Study, the renewal of which is being proposed in this application, built on the valuable data available in ARIC and ARIC-NCS. By focusing on brain amyloid-? deposition, which in leading hypotheses is responsible for the development of AD, the ARIC-PET study further evaluated the associations between midlife vascular risk factors and AD. In the initial phase of this study, we completed 347 brain amyloid PET scans, using florbetapir PET, among participants from three ARIC sites. We found higher rates of brain amyloid in participants who were older, female, carried an APOE ?4 allele (the primary genetic risk factor for AD), and who were of black race. Although our data did not support a general association between midlife vascular risk factors and brain amyloid, for persons with ?two hits?: a high genetic risk (carriers of an APOE ?4 allele) and elevated midlife vascular risk, our data do suggest more brain amyloid deposition. Finally, our data suggest that cognition is worse among participants who have both elevated brain amyloid and high amounts of brain cerebrovascular disease, on MRI. This renewal application proposes a repeat brain MRI and florbetapir (amyloid) PET scan among all surviving non-demented participants of ARIC-PET, to evaluate how vascular risk factors and brain subclinical vascular changes and APOE genotype each contribute to the progression of brain amyloid as well as the progression of clinical cognitive status, including conversion to mild cognitive impairment and dementia. Further, we will evaluate progression of brain cerebrovascular changes as a risk factor for progression of brain amyloid and clinical cognitive status, which we hypothesize may provide a critical link to explain some of our observed racial disparities in amyloid deposition rates. The ARIC-PET cohort provides unique data in a biracial sample; data from its renewal could identify important targets for prevention.

Public Health Relevance

Increasing evidence suggests that vascular risk factors play a major role in the development of dementia, including Alzheimer?s Disease. The Atherosclerosis Risk in Communities (ARIC)-PET Amyloid imaging study used PET scans to further understand the role of vascular disease in Alzheimer?s, and the studies proposed in this renewal will test how change in vascular disease relates to change in brain amyloid and cognition. Vascular risk factors and vascular disease may represent a treatable way to reduce the burden of dementia in the US and worldwide.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
2R01AG040282-06
Application #
9185481
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Hsiao, John
Project Start
2011-09-15
Project End
2021-04-30
Budget Start
2016-09-15
Budget End
2017-04-30
Support Year
6
Fiscal Year
2016
Total Cost
$761,685
Indirect Cost
$207,872
Name
Johns Hopkins University
Department
Neurology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Gottesman, Rebecca F; Schneider, Andrea L C; Zhou, Yun et al. (2016) The ARIC-PET amyloid imaging study: Brain amyloid differences by age, race, sex, and APOE. Neurology 87:473-80
Gross, Alden L; Power, Melinda C; Albert, Marilyn S et al. (2015) Application of Latent Variable Methods to the Study of Cognitive Decline When Tests Change over Time. Epidemiology 26:878-87
Rawlings, Andreea M; Sharrett, A Richey; Schneider, Andrea L C et al. (2014) Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 161:785-93
Koton, Silvia; Schneider, Andrea L C; Rosamond, Wayne D et al. (2014) Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 312:259-68
Chik, Yolanda; Gottesman, Rebecca F; Zeiler, Steven R et al. (2012) Differentiation of transverse sinus thrombosis from congenitally atretic cerebral transverse sinus with CT. Stroke 43:1968-70
Gottesman, Rebecca F; Sojkova, Jitka; Beason-Held, Lori L et al. (2012) Patterns of regional cerebral blood flow associated with low hemoglobin in the Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci 67:963-9
Fornage, Myriam; Debette, Stephanie; Bis, Joshua C et al. (2011) Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 69:928-39
Pathan, S S; Gottesman, R F; Mosley, T H et al. (2011) Association of lung function with cognitive decline and dementia: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Neurol 18:888-98
Christman, A L; Matsushita, K; Gottesman, R F et al. (2011) Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 54:1645-52